Steven Julious

Have just received the authors copy the 2nd edition of my book. Sample Sizes for Clinical Trials It is due out 21 June #statstwitter #epitwitter #ClinicalTrials #clinicalresearch @ScHARRSheffield @ScHARR_DTS @CTRU_Sheffield

If anyone can help with this survey or school age children it would be appreciated Please share and/or post to any persons or groups that may be interested....

Had a paper published with @Flight_LG and @Alan_Brennan entitled Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges doi.org/10.1186/s12874…

The protocol for MissionEB - a randomised, double-blinded, placebo-controlled, two-centre, crossover trial - a study to assess mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa has been published doi.org/10.1136/bmjope…

A great talk by @JamesSalsbury at #sct2025 entitled Assurance methods for designing a survival trial with delayed treatment effects

Attending an excellent talk by @NikkiTotton entitled at #SCT2025 entitled Using benefit risk methods to adjust the non-inferiority margin based on treatment benefits

We recommend that the conditional frailty model be used for these data in trials, including cluster randomised trials, to help to explain changes in event risk over time and assist clinical interpretation

Had a paper published with Kelly Grant on the analysis of recurrent events in clinical trials doi.org/10.1177/096228…

In clinical trials it is not only potential benefits that should be measured - it is crucially important that any potential #harms are also investigated 1/7 #MethodologyMonday #118

New Publication 🔊: Trials special series - the collection, analysis and reporting of adverse events in randomised controlled trials by @RachPips & @VR_Cornelius trialsjournal.biomedcentral.com/articles/10.11…

Today's date 5-2-25 Is a palindrome

My PhD student is undertaking a DELPHI on reporting of sample sizes with studies with adaptive designs in protocols and grants. Please fill in if you can

Just had a paper published led by @HollyTibble with researchers from @AUKCAR on using routine data in research

My paper with Amy Whitehead Mike Campbell & Cindy Cooper Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable Has been cited 1000 times doi.org/10.1177/096228…

@DrLauraAGray Congratulations Laura

Nearly half of studies did not justify their non-inferiority limit

The paper found the use of term "non-inferioroity" increased with the publication of the CONSORT Non-inferiority Guidelines

Just had a paper published entitled "A review of UK publicly funded non-inferiority trials: is the design more inferior than it should be?" Led by Nikki Totton with Stephen Walters and Elizabeth Coates doi.org/10.1186/s13063…

The timing of the first inteim analysis between industry and publicly funded trials is quite marked. For industry studies the first interim is after 50% of the information fration. By comparison for publicly funded trials the timing is bi-modal

For industry studies 68% have just one interim analysis compared to 51% for publicly funded

Justed had paper published with @qiangzh83769692 , @mdimairo , Jen Lewis and Zihang Yu entitled "Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications" doi.org/10.1186/s12874…